Claims for Patent: 9,101,559

Summary for Patent: 9,101,559

Title:	Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
Abstract:	The present invention is directed to methods of preventing central nervous system leukemia, treating T-cell acute lymphoblastic leukemia, and treating immune system disorders associated with CCR7-CCL19 mediated signaling. Suitable therapeutic agents for inhibiting CCR7-CCL19 signaling and methods of identifying additional therapeutic agents useful in the methods of the present invention are also disclosed.
Inventor(s):	Aifantis; Iannis (Brooklyn, NY), Buonamici; Silvia (Boston, MA)
Assignee:	New York University (New York, NY)
Application Number:	12/776,920
Patent Claims:	1. A method of inhibiting development of central nervous system leukemia in a subject, said method comprising: selecting a subject having T-cell acute lymphoblastic leukemia, wherein said subject does not have central nervous system leukemia; providing a CCR7 antibody; and administering the CCR7 antibody to the selected subject under conditions effective to inhibit development of central nervous system leukemia in the selected subject. 2. The method according to claim 1, wherein the CCR7 antibody is a human monoclonal antibody or an active binding fragment thereof. 3. The method according to claim 1, further comprising: administering to the selected subject a therapeutic agent that inhibits Notch-1 selected from the group consisting of [(2S)-2-{[(3,5-Difluorophenyl)acetyl]amino}-N-[(3S)1-methyl-2-oxo-5-pheny- l-2,3-dihydro-1 H-1, 4-benzodiazepin-3-yl] propanamide](CompE), N-[N-(3,5-difluorophenacetyl)-L-alanyl]-Sphenylglycine-t-butylester (DAPT), LY411575, (5S)-(t-Butoxycarbonylamino)-6-phenyl-(4R)hydroxy-(2R)benzylhexanoyl)-L-l- eu-L-phe-amide (L-685,458), L-852,647, MW167, WPE-III-31, LY450139, MRK003, R-flurbiprofen ([1,1'-Biphenyl]-4-acetic acid, 2-fluoro-alpha- methyl), NGX-555, E2012, GSI-1, Begacestat (2-Thiophenesulfonamide, 5- chloro-N-[(1S)-3.sub.13,3-trifluoro-1-(hydroxymethyl)-2-(trifluoromethyl)- propyl]-), NIC5-15, and CHF-5074. 4. The method according to claim 1 further comprising: administering a chemotherapeutic agent to the subject. 5. The method according to claim 4, wherein the chemotherapeutic agent is selected from the group consisting of cytarabine, vincristine, prednisone, daunorubicin, PEG asparaginase, methotrexate, and leucovorin. 6. A method of treating T-cell acute lymphoblastic leukemia in a subject, said method comprising: selecting a subject having T-cell acute lymphoblastic leukemia, wherein said subject does not have central nervous system leukemia and administering a cocktail of chemotherapeutic agents and a CCR7 antibody under conditions effective to treat T-cell acute lymphoblastic leukemia in the selected subject. 7. The method according to claim 6, wherein the cocktail of chemotherapeutic agents comprises two or more chemotherapeutic agents selected from the group consisting of cytarabine, vincristine, prednisone, daunorubicin, PEG asparaginase, methotrexate, and leucovorin. 8. The method according to claim 6, wherein the CCR7 antibody is a human monoclonal antibody or an active binding fragment thereof.

Details for Patent 9,101,559

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2029-05-08